EPIRUS Biopharmaceuticals Inc. / Sun Pharmaceutical Industries / FY 2014 Ranbaxy Laboratories Limited / Sun Pharma Merger / Novel Drug Delivery Systems / Daiichi Sankyo Group / Immediate Release Company / DAIICHI SANKYO COMPANY LIMITED / Rs.711 Mn / Ranbaxy Laboratories Ltd. / Sun Pharma / Tokyo Stock Exchange / /
Continent
Africa / North America / /
Country
Ivory Coast / Germany / Senegal / Guinea / Sri Lanka / Thailand / Kenya / Malaysia / Japan / Russia / United States / Uganda / Brazil / Australia / Nigeria / United Kingdom / Ukraine / Spain / India / Cameroon / /
Currency
Rs / / /
Event
FDA Phase / M&A / Business Partnership / /
Facility
High Court of Punjab / United States District Court / / /
CORPORATE OFFICE / High Court of Punjab and Haryana / United States District Court for the District of Massachusetts / Federal Trade Commission / Competition Commission of India / REGISTERED OFFICE / FDA / L24231PB1961PLC003747 CORPORATE OFFICE / /
HEAD OFFICE / Koji Ogawa Head / Director / President and CEO / CEO & Managing Director / Corporate Officer / Vice President / Corporate Communications Department Telephone / General Manager / Corporate Communications email / Representative / Manager - Corporate Communications Email / /
Product
esomeprazole magnesium / Fenofibrate Capsules / USA / /
ProvinceOrState
HARYANA / Punjab / Massachusetts / /
Region
East Europe / Middle East / West Europe / North Europe / /
Microsoft Word - 20150129_COVER LETTER_Ranbaxy Q3 FY 2015 results.docx